BRPI0401742B8 - composto análogo do ritonavir útil como inibidor de protease retroviral, preparação do composto análogo do ritonavir e composição farmacêutica do composto análogo do ritonavir - Google Patents

composto análogo do ritonavir útil como inibidor de protease retroviral, preparação do composto análogo do ritonavir e composição farmacêutica do composto análogo do ritonavir

Info

Publication number
BRPI0401742B8
BRPI0401742B8 BRPI0401742A BRPI0401742A BRPI0401742B8 BR PI0401742 B8 BRPI0401742 B8 BR PI0401742B8 BR PI0401742 A BRPI0401742 A BR PI0401742A BR PI0401742 A BRPI0401742 A BR PI0401742A BR PI0401742 B8 BRPI0401742 B8 BR PI0401742B8
Authority
BR
Brazil
Prior art keywords
ritonavir
analogue compound
analogue
pharmaceutical composition
protease inhibitor
Prior art date
Application number
BRPI0401742A
Other languages
English (en)
Inventor
Roberto Fuzeto Cláudio
Cecília Barel Daniela
Moraes Godinho De Oliveira Kesley
Alice Bockelmann Maria
Puggina De Freitas Matheus
Soares Rosato Simone
Boscaro Vernucci Thiago
Original Assignee
Cristalia Produtos Quim Farmaceuticos Ltda
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cristalia Produtos Quim Farmaceuticos Ltda filed Critical Cristalia Produtos Quim Farmaceuticos Ltda
Priority to BRPI0401742A priority Critical patent/BRPI0401742B8/pt
Priority to MXPA06013188A priority patent/MXPA06013188A/es
Priority to AT05738457T priority patent/ATE480526T1/de
Priority to US11/596,469 priority patent/US7763733B2/en
Priority to EP05738457A priority patent/EP1751125B1/en
Priority to DE602005023437T priority patent/DE602005023437D1/de
Priority to PCT/BR2005/000077 priority patent/WO2005111006A1/en
Priority to JP2007511791A priority patent/JP4993747B2/ja
Priority to HK07113471.4A priority patent/HK1107699B/xx
Priority to CN200580021778A priority patent/CN100584833C/zh
Publication of BRPI0401742A publication Critical patent/BRPI0401742A/pt
Publication of BRPI0401742B1 publication Critical patent/BRPI0401742B1/pt
Publication of BRPI0401742B8 publication Critical patent/BRPI0401742B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

composto análogo do ritonavir útil como inibidor de protease retroviral, preparação do composto análogo do ritonavir e composição farmacêutica do composto análogo do ritonavir a presente invenção descreve a síntese de um novo composto análogo do ritonavir que apresenta atividade significativamente superior ao ritonavir na inibição da protease do hiv. são também descritos o uso do composto análogo do ritonavir da presente invenção, ou seu sal, éster ou pro-droga, como ingrediente ativo em composições farmacêuticas bem como o uso do composto e das composições farmacêuticas em medicina, particularmente no tratamento de infecção por hiv, sozinho ou em combinação com outros medicamentos anti-hiv.
BRPI0401742A 2004-05-13 2004-05-13 composto análogo do ritonavir útil como inibidor de protease retroviral, preparação do composto análogo do ritonavir e composição farmacêutica do composto análogo do ritonavir BRPI0401742B8 (pt)

Priority Applications (10)

Application Number Priority Date Filing Date Title
BRPI0401742A BRPI0401742B8 (pt) 2004-05-13 2004-05-13 composto análogo do ritonavir útil como inibidor de protease retroviral, preparação do composto análogo do ritonavir e composição farmacêutica do composto análogo do ritonavir
MXPA06013188A MXPA06013188A (es) 2004-05-13 2005-05-11 Compuesto analogo de ritonavir util como inhibidor de proteasa retroviral, preparacion del compuesto analogo de ritonavir y composicion farmaceutica para el compuesto analogo de ritonavir.
AT05738457T ATE480526T1 (de) 2004-05-13 2005-05-11 Als inhibitor von retroviraler protease geeignete ritonavir-analoge verbindung, herstellung der ritonavir-analogen verbindung und pharmazeutische zusammenetzung für die ritonavir-analoge verbindung
US11/596,469 US7763733B2 (en) 2004-05-13 2005-05-11 Ritonavir analogous compound useful as retroviral protease inhibitor, preparation of the ritonavir analogous compound and pharmaceutical composition for the ritonavir analogous compound
EP05738457A EP1751125B1 (en) 2004-05-13 2005-05-11 Ritonavir analogous compound useful as retroviral protease inhibitor, preparation of the ritonavir analogous compound and pharmaceutical composition for the ritonavir analogous compound.
DE602005023437T DE602005023437D1 (de) 2004-05-13 2005-05-11 Als inhibitor von retroviraler protease geeignete ritonavir-analoge verbindung, herstellung der ritonavir-analogen verbindung und pharmazeutische zusammenetzung für die ritonavir-analoge verbindung
PCT/BR2005/000077 WO2005111006A1 (en) 2004-05-13 2005-05-11 Ritonavir analogous compound useful as retroviral protease inhibitor, preparation of the ritonavir analogous compound and pharmaceutical composition for the ritonavir analogous compound.
JP2007511791A JP4993747B2 (ja) 2004-05-13 2005-05-11 レトロウイルスプロテアーゼ阻害剤として有用なリトナビル類似化合物、そのリトナビル類似化合物の製造方法及びそのリトナビル類似化合物の薬学的組成物
HK07113471.4A HK1107699B (en) 2004-05-13 2005-05-11 Ritonavir analogous compound useful as retroviral protease inhibitor, preparation of the ritonavir analogous compound and pharmaceutical composition for the ritonavir analogous compound
CN200580021778A CN100584833C (zh) 2004-05-13 2005-05-11 可用作逆转录病毒蛋白酶抑制剂的利托那韦类似化合物、利托那韦类似化合物的制备和利托那韦类似化合物的药物组合物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BRPI0401742A BRPI0401742B8 (pt) 2004-05-13 2004-05-13 composto análogo do ritonavir útil como inibidor de protease retroviral, preparação do composto análogo do ritonavir e composição farmacêutica do composto análogo do ritonavir

Publications (3)

Publication Number Publication Date
BRPI0401742A BRPI0401742A (pt) 2006-01-10
BRPI0401742B1 BRPI0401742B1 (pt) 2019-04-16
BRPI0401742B8 true BRPI0401742B8 (pt) 2021-05-25

Family

ID=36072150

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0401742A BRPI0401742B8 (pt) 2004-05-13 2004-05-13 composto análogo do ritonavir útil como inibidor de protease retroviral, preparação do composto análogo do ritonavir e composição farmacêutica do composto análogo do ritonavir

Country Status (9)

Country Link
US (1) US7763733B2 (pt)
EP (1) EP1751125B1 (pt)
JP (1) JP4993747B2 (pt)
CN (1) CN100584833C (pt)
AT (1) ATE480526T1 (pt)
BR (1) BRPI0401742B8 (pt)
DE (1) DE602005023437D1 (pt)
MX (1) MXPA06013188A (pt)
WO (1) WO2005111006A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG183007A1 (en) 2006-07-07 2012-08-30 Gilead Sciences Inc Modulators of pharmacokinetic properties of therapeutics
WO2008027932A2 (en) * 2006-08-31 2008-03-06 Abbott Laboratories Cytochrome p450 oxidase inhibitors and uses thereof
PL3150586T3 (pl) 2007-02-23 2020-06-01 Gilead Sciences, Inc. Modulatory farmakokinetycznych właściwości środków terapeutycznych
EP2170851B1 (en) 2007-07-06 2013-09-04 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
CN102786494B (zh) * 2012-07-26 2016-01-06 合肥华方医药科技有限公司 利托那韦异构体杂质的合成研究及控制方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5354866A (en) * 1989-05-23 1994-10-11 Abbott Laboratories Retroviral protease inhibiting compounds
US5552558A (en) * 1989-05-23 1996-09-03 Abbott Laboratories Retroviral protease inhibiting compounds
IE913840A1 (en) * 1990-11-20 1992-05-20 Abbott Lab Retroviral protease inhibiting compounds
US5567823A (en) * 1995-06-06 1996-10-22 Abbott Laboratories Process for the preparation of an HIV protease inhibiting compound
US5914332A (en) 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
ZA9710071B (en) 1996-11-21 1998-05-25 Abbott Lab Pharmaceutical composition.
CO5090830A1 (es) 1998-07-20 2001-10-30 Abbott Lab Poliformo de un agente farmaceutico

Also Published As

Publication number Publication date
EP1751125A1 (en) 2007-02-14
US7763733B2 (en) 2010-07-27
DE602005023437D1 (de) 2010-10-21
JP4993747B2 (ja) 2012-08-08
EP1751125B1 (en) 2010-09-08
CN1980907A (zh) 2007-06-13
BRPI0401742B1 (pt) 2019-04-16
WO2005111006A1 (en) 2005-11-24
JP2007537166A (ja) 2007-12-20
CN100584833C (zh) 2010-01-27
MXPA06013188A (es) 2007-02-14
ATE480526T1 (de) 2010-09-15
HK1107699A1 (zh) 2008-04-11
US20070244168A1 (en) 2007-10-18
BRPI0401742A (pt) 2006-01-10

Similar Documents

Publication Publication Date Title
BR0214343A (pt) Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1
MXPA04004837A (es) Inhibidores de 11-??-hidroxiesteroide deshidrogenasa de tipo 1.
MX2012007410A (es) Compuestos antivirales novedosos.
BRPI0407306A (pt) 1,2,4- triazinas de inibição de hiv
DE602006014990D1 (de) Intranasale verabreichung von schnell wirkendem insulin
BR0211742A (pt) Derivados de aminoisoxazole ativos como inibidores de cinase
BRPI0611717A2 (pt) composto, composiÇço farmacÊutica e uso do composto
BRPI0508540A (pt) composto, composição farmacêutica, e, uso de um composto
AR027391A1 (es) Composiciones farmaceuticas de toxina botulinica
UY29410A1 (es) Composiciones farmacéuticas en base a metilamidas del ácido 4-(4-/-3(-4-cloro-3-trifluorometifenil)ureido)fenoxi)piridin-2-carboxílico, procedimiento de preparación y aplicaciones.
EA200970081A1 (ru) Соединения, обладающие потенциирующим действием в отношении активности этионамида, и их применения
CO5640037A2 (es) Derivados de la quinazolina para el tratamiento del cancer
DK1680128T3 (da) Myo-inositolhexaphosphat til topisk anvendelse
BR112015019412A8 (pt) inibidores de bace1, seus usos, e composição farmacêutica
DK1987063T3 (da) Peptider og peptidderivater, fremstilling deraf samt deres anvendelse til fremstilling af en terapeutisk og/eller præventivt aktiv farmaceutisk sammensætning
WO2005075471A3 (en) Thiazol-compounds as 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors
BRPI0616536B8 (pt) uso de um éster de ácido hidroxibenzoico
BRPI0409878A (pt) compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos
BRPI0401742B8 (pt) composto análogo do ritonavir útil como inibidor de protease retroviral, preparação do composto análogo do ritonavir e composição farmacêutica do composto análogo do ritonavir
BRPI0519351A2 (pt) medicamentos para o tratamento ou prevenÇço de doenÇas fibràticas
WO2006042478A8 (fr) Inhibiteurs de petites molecules de la protease principale des coronavirus, leur preparation et utilisation
RU2007104774A (ru) Комбинация анти-вич ингибиторов обратной транскриптазы и протеазы
BRPI0514724A (pt) inibidores da enzima hiv integrase
BRPI0417492A (pt) composições compreendendo um inibidor de protease de hiv
DE50113974D1 (de) Kombinationspräparate von 3-n-formylhydroxylaminopropylphosphonsäurederivaten oder 3-n-acetylhydroxylaminopropylphosphonsäurederivaten mit speziellen pharmazeutischen wirkstoffen

Legal Events

Date Code Title Description
B03A Publication of a patent application or of a certificate of addition of invention [chapter 3.1 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA INT.CL: C07D 277/24, A61K 31/426, A61P 31/00

Ipc: C07D 277/24 (2011.01), A61K 31/426 (2011.01)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 16/04/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 16/04/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/05/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2827 DE 11-03-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.